

## [New Drug Approvals](#)

**Generic Name (Trade Name—Company)**

June 13, 2011

**Uses/Notes**

Adjunctive treatment of partial-onset seizures in adults

**Ezogabine**

**(Potiga—Valeant, GlaxoSmithKline)**

**Indicated for adjunct treatment of partial-onset seizures**

**Source URL:**

<http://aphanet.org/indicated-adjunct-treatment-partial-onset-seizures>

Ezogabine is the first neuronal potassium channel opener approved for the management of patients with epilepsy. Activation of potassium currents mediated by the KCNQ family of ion channels results in stabilization of the resting membrane potential and a reduction in brain excitability. Patients randomized to total daily maintenance ezogabine dosages of 600 mg/d, 900 mg/d, or 1,200 mg/d had significant reductions in seizure frequency over a 28-day period, compared with placebo. According to a [press release](#) by Valeant and GlaxoSmithKline, the drug will not be available until later this year because FDA has recommended that the drug be classified as a controlled substance due to its euphoric effects. Final classification is still under review by the Drug Enforcement Administration.

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.